Pharmaceutical Serialization, a Global Effort to Combat Counterfeit Medicines

1. Gostin L, Buckley G, Kelley P. Stemming the global trade in falsified and substandard medicines. JAMA. 2013;309:1693-1694.10.1001/jama.2013.304823579391Search in Google Scholar

2. Hamilton WL, Doyle C, Halliwell-Ewen M, Lambert G. Public Health Interventions to Protect against Falsified Medicines: A Systematic Review of International, National and Local Policies. Health Policy Plan. 2016;31:1448–1466.10.1093/heapol/czw06227311827Search in Google Scholar

3. Haleem RM, Salem MY, Fatahallah FA, Abdelfattah LE. Quality in the pharmaceutical industry - A literature review. Saudi Pharm J. 2015;23:463–469.10.1016/j.jsps.2013.11.004460591726594110Search in Google Scholar

4. Cordon C, Garcia-Milà P, FerreiroVilarino T, Caballero P. Strategy is Digital: How Companies Can Use Big Data in the Value Chain. New York: Springer International Publishing; 2016, 47-64.10.1007/978-3-319-31132-6_3Search in Google Scholar

5. Chiacchio F, Compagno L, D’Urso D, Velardita L, Sandner P. A Decentralised Application for the Traceability Process in the Pharma Industry. Procedia Manufacturing, International Conference on Industry 4.0 and Smart Manufacturing. 2020;42:362–369.Search in Google Scholar

6. Trenfield SJ, Xian Tan H, Awad A, et al. Track-and-Trace: Novel Anti-Counterfeit Measures for 3D Printed Personalized Drug Products Using Smart Material Inks. International Journal of Pharmaceutics. 2019;567:e118443.10.1016/j.ijpharm.2019.06.03431212052Search in Google Scholar

7. Bandyopadhyay S. The Internet And Gray Marketing. International Business & Economics Research Journal. 2010;9:95-102.10.19030/iber.v9i6.588Search in Google Scholar

8. Brechtelsbauer ED, Pennell B, Durham M, Hertig JB, Weber RJ. Review of the 2015 Drug Supply Chain Security Act. Hosp Pharm. 2016;51:493–500.10.1310/hpj5106-493491199227354753Search in Google Scholar

9. U.S. Food&Drug Administration. Counterfeit medicine. https://www.fda.gov/drugs/buying-using-medicine-safely/counterfeit-medicineSearch in Google Scholar

10. Center for Disease Control and Prevention. Counterfeit medicine. https://wwwnc.cdc.gov/travel/page/counterfeit-medicineSearch in Google Scholar

11. Interpol. Fake medicines. https://www.interpol.int/en/Crimes/Illicit-goods/Shop-safely/Fake-medicinesSearch in Google Scholar

12. Williams L, McKnight E. The real impact of counterfeit medications. US Pharmacist. 2014;39:44-46.Search in Google Scholar

13. Ozawa S, Evans DR, Bessias S, et al. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. JAMA Netw Open. 2018;1:e181662.10.1001/jamanetworkopen.2018.1662632428030646106Search in Google Scholar

14. Kelesidis T, Falagas ME. Substandard/Counterfeit Antimicrobial Drugs. Clin Microbiol Rev. 2015;28:443-464.10.1128/CMR.00072-14440295825788516Search in Google Scholar

15. Almuzaini T, Choonara I, Sammons H. Substandard and Counterfeit Medicines: A Systematic Review of the Literature. BMJ Open. 2013;3:e002923.10.1136/bmjopen-2013-002923375204923955188Search in Google Scholar

16. Lee JH, Park HN, Kim NS, et al. Application of Screening Methods for Weight-Loss Compounds and Identification of New Impurities in Counterfeit Drugs. Forensic Sci Int. 2019;303:e109932.10.1016/j.forsciint.2019.10993231473560Search in Google Scholar

17. Soares F, Anzanello MJ, Fogliatto FS, Ortiz RS, Mariotti KC, Ferrao MF. Enhancing counterfeit and illicit medicines grouping via feature selection and X-ray fluorescence spectrometry. J Pharm Biomed Anal. 2019;174:198-205.10.1016/j.jpba.2019.05.06431174131Search in Google Scholar

18. Naughton B, Roberts L, Dopson S, Chapman S, Brindley D. Effectiveness of Medicines Authentication Technology to Detect Counterfeit, Recalled and Expired Medicines: A Two-Stage Quantitative Secondary Care Study. BMJ. 2016;12:e013837.10.1136/bmjopen-2016-013837516865527940634Search in Google Scholar

19. Kovacs S, Hawes SE, Maley SN, Mosites E, Wong L, Stergachis A. Technologies for Detecting Falsified and Substandard Drugs in Low and Middle-Income Countries. PLoS One. 2014;9:e90601.10.1371/journal.pone.0090601396673824671033Search in Google Scholar

20. Martino R, Malet-Martino M, Gilard V, Balayssac S. Counterfeit drugs: analytical techniques for their identification. Anal Bioanal Chem. 2010;398:77-92.10.1007/s00216-010-3748-y20437031Search in Google Scholar

21. Bansal D, Malla S, Gudala K, Tiwari P. Anti-Counterfeit Technologies: A Pharmaceutical Industry Perspective. Sci Pharm. 2013;81:1-13.10.3797/scipharm.1202-03361766623641326Search in Google Scholar

22. Mackey TK, Nayyar GA. Review of Existing and Emerging Digital Technologies to Combat the Global Trade in Fake Medicines. Expert Opin Drug Saf. 2017;16:587-602.10.1080/14740338.2017.131322728349715Search in Google Scholar

23. Deus L. Technological Roles in Combating Drug Diversion and Counterfeiting. Journal of Pharmacy Practice. 2006;19:146-152.10.1177/0897190006292943Search in Google Scholar

24. U.S. Food&Drug Administration. FDA In Brief: FDA advances policies related to bolstering security of drug products in the U.S. supply chain. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-advances-policies-related-bolstering-security-drug-products-us-supply-chainSearch in Google Scholar

25. Chiacchio F, D’Urso D, Compagno L, Chiarenza M, Velardita L. Towards a Blockchain Based Traceability Process: A Case Study from Pharma Industry, in Ameri F, Stecke KE, von Cieminski G, Kiritsis D (eds): Advances in Production Management Systems. Production Management for the Factory of the Future. Springer International Publishing, Cham Switzerland, 2019, 451–45710.1007/978-3-030-30000-5_56Search in Google Scholar

26. Taylor D. RFID in the Pharmaceutical Industry: Addressing Counterfeits with Technology. J Med Syst. 2014;38(141):1-5.10.1007/s10916-014-0141-y25308613Search in Google Scholar

27. Center for Disease Control and Prevention. The drug Supply Chain Security Act and 2D Vaccine Barcodes. https://www.cdc.gov/vaccines/programs/iis/2d-vaccine-barcodes/downloads/Drug-Supply-Chain-Security-Act-508.pdfSearch in Google Scholar

28. Naughton BD. Medicine Authentication Technology: A Quantitative Study of Incorrect Quarantine, Average Response Times and Offline Issues in a Hospital Setting. BMJ. 2019;9:e026619.10.1136/bmjopen-2018-026619Search in Google Scholar

29. Gutorova N, Zhytnyi O, Soloviov O. Falsification of Medical Products: Criminal Law Mechanism Combating Threats to Public Health. Wiad Lek. 2019;72:856-861.10.36740/WLek201905124Search in Google Scholar

30. Greenberg MA. Serialisation: Benefits Beyond Regulatory Compliance. Ther Innov Regul Sci. 2014;48:22-27.10.1177/2168479014553034Search in Google Scholar

31. Lizano-Díez I, Figueiredo-Escribá C, Piñero-López MÁ, Lastra CF, Mariño EL, Modamio P. Prevention strategies to identify LASA errors: building and sustaining a culture of patient safety. BMC Health Services Research. 2020;20:63.10.1186/s12913-020-4922-3Search in Google Scholar

32. European Medicine Agency. Sistemul European de reglementare pentru medicamente. https://www.ema.europa.eu/en/documents/leaflet/european-regulatory-system-medicines-european-medicines-agency-consistent-approach-medicines_ro.pdfSearch in Google Scholar

33. European Medicine Agency. Pharmacovigilance Risk Assessment Committee (PRAC):Work Plan 2019 https://www.ema.europa.eu/en/documents/work-programme/pharmacovigilance-risk-assessment-committee-prac-work-plan-2019_en.pdfSearch in Google Scholar

34. Horalek J, Sobeslav V. Track & Trace System with Serialization Prototyping Methodology for Pharmaceutical Industry in EU, in Younas M, Awan I, Holubova I, (eds): Mobile Web and Intelligent Information Systems. Springer International Publishing AG, Cham Switzerland, 2017, 177-186.10.1007/978-3-319-65515-4_15Search in Google Scholar

35. GOVINFO. Public Law 113 - 54 - Drug Quality and Security Act. https://www.govinfo.gov/app/details/PLAW-113publ54Search in Google Scholar

36. U.S. Food&Drug Administration. Drug Supply Chain Security Act Law and Policies. https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/drug-supply-chain-security-act-law-and-policiesSearch in Google Scholar

37. U.S. Food&Drug Administration. Product Identifier Requirements Under the Drug Supply Chain Security Act – Compliance Policy Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-identifier-requirements-under-drug-supply-chain-security-act-compliance-policy-guidanceSearch in Google Scholar

38. Fayzrakhmanov NF. Fighting Trafficking of Falsified and Substandard Medicinal Products in Russia. Int J Risk Saf Med. 2015;27:37-40.10.3233/JRS-150681Search in Google Scholar

39. European Union Law. Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products. http://data.europa.eu/eli/dir/2011/62/ojSearch in Google Scholar

40. European Medicines Verification Organisation. https://emvo-medicines.eu/Search in Google Scholar

41. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Overview of ICH. https://admin.ich.org/sites/default/files/2019-11/OverviewOfICH_2019_1128_0.pdfSearch in Google Scholar

42. World Health Organization. WHO Global Surveillance and Monitoring System for substandard and falsified medical products, Reports and Executive summary. https://www.who.int/medicines/regulation/ssffc/publications/gsms-report-sf/en/Search in Google Scholar

43. European Medicine Agency. Buying medicines online https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/falsified-medicines/buying-medicines-onlineSearch in Google Scholar

44. Official Journal of the European Union. Commission Implementing (EU) No 699/2014. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:JOL_2014_184_R_0004&from=ENSearch in Google Scholar

45. Fight the Fakes. Partners. http://fightthefakes.com/partners/Search in Google Scholar

46. Newton PN, McGready R, Fernandez F, et al. Manslaughter by fake artesunate in Asia-will Africa be next?. PLOS Medicine. 2006;3:e324.10.1371/journal.pmed.0030324Search in Google Scholar

47. Laserson KF, Kenyon AS, Kenyon TA, Layloff T, Binkin NJ. Substandard tuberculosis drugs on the global market and their simple detection. Int J Tuberc Lung Dis. 2001;5:448-454.Search in Google Scholar

48. Taylor RB, Shakoor O, Behrens RH, et al. Pharmacopeial qualitz of drugs supplied by Nigerian pharmacies. Lancet. 2001;357:1933-1936.10.1016/S0140-6736(00)05065-0Search in Google Scholar

49. Government of Canada. Recalls and safety alerts. A small number of bottles of the antibiotic Rofact (rifampicin) may contain a different drug. http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2009/13384a-eng.phpSearch in Google Scholar

50. Government of Canada. Recalls and safety alerts. Immediate recall by Mylan Pharmaceuticals: potential serious risk due to mislabeling of products. http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/13584a-eng.phpSearch in Google Scholar

51. L’Agence nationale de sécurité du médicament et des produits de santé. Historique d’une alerte résolue: Furosémide Teva 40 mg, comprimé sécable. https://www.ansm.sante.fr/Dossiers/Furosemide-Teva-40-mg-comprime-secable/Historique-d-une-alerte-resolue-Furosemide-Teva-40-mg-comprime-secable/(offset)/0Search in Google Scholar

52. Mackey TK, Cuomo R, Guerra C, Liang BA. After Counterfeit Avastin®--What Have We Learned and What Can Be Done?. Nat Rev Clin Oncol. 2015;12:302-308.10.1038/nrclinonc.2015.3525734637Search in Google Scholar

53. Petersen A, Held N, Heide L, Difäm-EPN Minilab Survey Group. Surveillance for Falsified and Substandard Medicines in Africa and Asia by Local Organisations Using the Low-Cost GPHF Minilab. PloS One. 2017;12: e0184165.10.1371/journal.pone.0184165558728428877208Search in Google Scholar

54. Attaran A, Barry D, Basheer S, et al. How to achieve international action on falsified and substandard medicine. BMJ. 2012;345:e7381.10.1136/bmj.e738123149211Search in Google Scholar

55. Kainer MA, Reagan DR, Nguyen DB, et al. Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med. 2012;367:2194-2203.10.1056/NEJMoa1212972466956223131029Search in Google Scholar

56. Twagirumukiza M, Cosijns A, Pringels E, Remon JP, Vervaet C, Van Bortel L. Influence of tropical climate conditions on the quality of antihypertensive drugs from Rwandan pharmacies. Am J Trop Med Hyg. 2009;81:776-781.10.4269/ajtmh.2009.09-010919861610Search in Google Scholar

57. Angeli DG, Trezza C. Quality and stability of ramipril generics/copies versus reference ramipril (Tritace): a 3 month stability comparative study. Clin Drug Investig. 2009; 29:667-676.10.2165/11315270-000000000-0000019715383Search in Google Scholar

58. Taylor PW, Keenan MHJ. Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane. Curr Med Res Opin. 2008;24:2019-2033.Search in Google Scholar

59. U.S. Food&Drug Administration. Recalls, Market withdrawals,& Safety Alerts https://www.fda.gov/safety/recalls-market-withdrawals-safety-alertsSearch in Google Scholar